TECX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Tectonic Therapeutic's net margin of --. Tectonic Therapeutic's return on equity of -- beat CEL-SCI's return on equity of --.

Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.76%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1188.67%. Given that CEL-SCI has higher upside potential than Tectonic Therapeutic, analysts believe CEL-SCI is more attractive than Tectonic Therapeutic.

Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Tectonic Therapeutic quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tectonic Therapeutic's net income of -$17.7M is lower than CEL-SCI's net income of -$6.9M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Tectonic Therapeutic's net margin of -416.75%. Tectonic Therapeutic's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.76%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 913.51%. Given that IGC Pharma has higher upside potential than Tectonic Therapeutic, analysts believe IGC Pharma is more attractive than Tectonic Therapeutic.

Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Tectonic Therapeutic quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Tectonic Therapeutic's net income of -$17.7M is lower than IGC Pharma's net income of -$1.7M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 21.64x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Tectonic Therapeutic's net margin of 8.48%. Tectonic Therapeutic's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.76%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.65%. Given that Tectonic Therapeutic has higher upside potential than Eli Lilly and, analysts believe Tectonic Therapeutic is more attractive than Eli Lilly and.

Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tectonic Therapeutic quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Tectonic Therapeutic's net income of -$17.7M is lower than Eli Lilly and's net income of $970.3M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 84.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 17.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Tectonic Therapeutic's net margin of -49.65%. Tectonic Therapeutic's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 58.76%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than Tectonic Therapeutic, analysts believe NovaBay Pharmaceuticals is more attractive than Tectonic Therapeutic.

Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Tectonic Therapeutic quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tectonic Therapeutic's net income of -$17.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.